These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27300106)

  • 1. Intraoperative Defibrillation Testing Should Not Be Generally Abandoned for All ICD Procedures-A Multicenter Study on 4,572 Consecutive Patients.
    Ziegelhoeffer T; Siebel A; Markewitz A; Doll N; Bärsch V; Reinartz M; Oswald B; Bimmel D; Meyer A; Weimar T; Walther T; Burger H
    Thorac Cardiovasc Surg; 2016 Dec; 64(8):679-687. PubMed ID: 27300106
    [No Abstract]   [Full Text] [Related]  

  • 2. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial.
    Vamos M; Healey JS; Wang J; Duray GZ; Connolly SJ; van Erven L; Vinolas X; Neuzner J; Glikson M; Hohnloser SH
    Heart Rhythm; 2016 Feb; 13(2):504-10. PubMed ID: 26569461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
    Madhavan M; Waks JW; Friedman PA; Kramer DB; Buxton AE; Noseworthy PA; Mehta RA; Hodge DO; Higgins AY; Webster TL; Witt CM; Cha YM; Gersh BJ
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):e003283. PubMed ID: 26921377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of defibrillation testing in an unselected population of 2,120 consecutive patients undergoing first implantable cardioverter-defibrillator implant.
    Brignole M; Occhetta E; Bongiorni MG; Proclemer A; Favale S; Iacopino S; Calò L; Vado A; Buja G; Mascioli G; Quartieri F; Tritto M; Parravicini U; Castro A; Tomasi C; Villani GQ; D'Acri MG; Klersy C; Gasparini M;
    J Am Coll Cardiol; 2012 Sep; 60(11):981-7. PubMed ID: 22858384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Right versus left parasternal electrode position in the entirely subcutaneous ICD.
    Bettin M; Dechering D; Frommeyer G; Larbig R; Löher A; Reinke F; Köbe J; Eckardt L
    Clin Res Cardiol; 2018 May; 107(5):389-394. PubMed ID: 29285623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C; Atienza F; Strasberg B; Arenal Á; Codner P; González-Torrecilla E; Datino T; Percal T; Almendral J; Ortiz M; Martins R; Martinez-Alzamora N; Fernandez Aviles F
    Cardiol J; 2015; 22(3):253-9. PubMed ID: 25179316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience.
    Aydin A; Hartel F; Schlüter M; Butter C; Köbe J; Seifert M; Gosau N; Hoffmann B; Hoffmann M; Vettorazzi E; Wilke I; Wegscheider K; Reichenspurner H; Eckardt L; Steven D; Willems S
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):913-9. PubMed ID: 22923274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of defibrillation threshold testing in the contemporary defibrillator patient population.
    Vischer AS; Sticherling C; Kühne MS; Osswald S; Schaer BA
    J Cardiovasc Electrophysiol; 2013 Apr; 24(4):437-41. PubMed ID: 23210803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of defibrillation threshold testing on burden of heart failure hospitalizations.
    Akdemir B; Li Y; Krishnan B; Adabag S; Tholakanahalli V; Benditt DG; Li JM
    Acta Cardiol; 2020 Jun; 75(3):226-232. PubMed ID: 31211930
    [No Abstract]   [Full Text] [Related]  

  • 14. Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy.
    Srinivasan NT; Patel KH; Qamar K; Taylor A; Bacà M; Providência R; Tome-Esteban M; Elliott PM; Lambiase PD
    Circ Arrhythm Electrophysiol; 2017 Apr; 10(4):. PubMed ID: 28408651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy.
    Maurizi N; Tanini I; Olivotto I; Amendola E; Limongelli G; Losi MA; Allocca G; Perego GB; Pieragnoli P; Ricciardi G; De Filippo P; Ferrari P; Quarta G; Viani S; Rapacciuolo A; Bongiorni MG; Cecchi F
    Int J Cardiol; 2017 Mar; 231():115-119. PubMed ID: 28073660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between atrial fibrillation-triggered implantable cardioverter-defibrillator (ICD) shocks and inappropriate shocks caused by lead failure: different impact on prognosis in clinical practice.
    Kleemann T; Hochadel M; Strauss M; Skarlos A; Seidl K; Zahn R
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):735-40. PubMed ID: 22313314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous implantable cardioverter-defibrillator and defibrillation testing: A propensity-matched pilot study.
    Forleo GB; Gasperetti A; Breitenstein A; Laredo M; Schiavone M; Ziacchi M; Vogler J; Ricciardi D; Palmisano P; Piro A; Compagnucci P; Waintraub X; Mitacchione G; Carrassa G; Russo G; De Bonis S; Angeletti A; Bisignani A; Picarelli F; Casella M; Bressi E; Rovaris G; Calò L; Santini L; Pignalberi C; Lavalle C; Viecca M; Pisanò E; Olivotto I; Curnis A; Dello Russo A; Tondo C; Love CJ; Di Biase L; Steffel J; Tilz R; Badenco N; Biffi M
    Heart Rhythm; 2021 Dec; 18(12):2072-2079. PubMed ID: 34214647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in the subcutaneous ICD.
    Willcox ME; Prutkin JM; Bardy GH
    Trends Cardiovasc Med; 2016 Aug; 26(6):526-35. PubMed ID: 27079889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.